Internal Medicine | Page 164 of 487 | Links Medicus Content Curation & Alerts in Medicine

Sweden, Denmark pause Moderna COVID-19 vaccine for younger age groups.

7 Oct, 2021 | 10:45h | UTC

Sweden, Denmark pause Moderna COVID-19 vaccine for younger age groups – Reuters

Large observational study suggests sleeve gastrectomy may be safer compared to gastric bypass in patients with severe obesity.

7 Oct, 2021 | 10:26h | UTC

Comparative Safety of Sleeve Gastrectomy and Gastric Bypass Up to 5 Years After Surgery in Patients With Severe Obesity – JAMA Surgery (free for a limited period)

Commentaries:

Compared to What?—Novel Methods to Approach Randomization for Long-term Bariatric Surgery Outcomes – JAMA Surgery (free for a limited period)

Of two common weight loss surgeries, one is safer but less effective – Michigan Medicine

Different risks and benefits leading to similar costs after sleeve gastrectomy and roux-en-y gastric bypass.

Laparoscopic roux-en-y gastric bypass vs. laparoscopic sleeve gastrectomy: 5-year outcomes of merged data from two randomized clinical trials

Randomized trial: no difference in quality of life and slightly greater weight loss with roux-en-y gastric bypass compared to laparoscopic sleeve gastrectomy at 7 years

Cohort study: comparing the 5-year diabetes outcomes of sleeve gastrectomy and gastric bypass

Cohort study: interventions and operations 5 years after bariatric surgery

Cohort study: risk of operative and nonoperative interventions after roux-en-y gastric bypass vs. vertical sleeve gastrectomy

Randomized trial: gastric bypass superior to sleeve gastrectomy for remission of type 2 diabetes

Research: laparoscopic sleeve gastrectomy vs laparoscopic roux-en-y gastric bypass

Commentary on Twitter

Study suggests that the safety benefits of sleeve gastrectomy persist up to 5 years after surgery; this information may help patients and surgeons make informed treatment decisions https://t.co/JuRQGh3byz

— JAMA Surgery (@JAMASurgery) October 6, 2021

Evidence and consensus-based recommendations for non-pharmacological treatment of fatigue, hand function loss, Raynaud’s phenomenon, and digital ulcers in patients with systemic sclerosis.

7 Oct, 2021 | 10:19h | UTC

Evidence and consensus-based recommendations for non-pharmacological treatment of fatigue, hand function loss, Raynaud’s phenomenon, and digital ulcers in patients with systemic sclerosis – Rheumatology

Opinion | Why Are Americans Still—Still!—Wearing Cloth Masks?

6 Oct, 2021 | 10:04h | UTC

Why Are Americans Still—Still!—Wearing Cloth Masks? – The Atlantic

Evidence shows that, yes, masks prevent COVID-19 – and surgical masks are the way to go.

Face masks for COVID pass their largest test yet – “A rigorous study finds that surgical masks are highly protective, but cloth masks fall short”.

[Preprint] Largest study of masks yet details their importance in fighting Covid-19.

Commentary on Twitter

Any mask is better than no mask, especially indoors. But for those who are at higher risk of severe disease or around lots of unvaccinated people, consider upgrading to an N95 (or equivalent) mask, which are more protective. https://t.co/vhNPadTP8O

— Dr. Tom Frieden (@DrTomFrieden) October 5, 2021

EMA recommendations on extra doses and boosters of BioNTech/Pfizer and Moderna mRNA vaccines.

6 Oct, 2021 | 10:15h | UTC

Comirnaty and Spikevax: EMA recommendations on extra doses and boosters – European Medicines Agency

Commentary on Twitter

EMA recommended additional doses and boosters for #Comirnaty and #Spikevax. https://t.co/qefPg2kMMO

In this context, see below what the difference between an additional dose and a #boosterdose is. pic.twitter.com/HeyOACbWXm

— EU Medicines Agency (@EMA_News) October 5, 2021

What we know — and don’t know — about Merck’s new Covid-19 pill.

6 Oct, 2021 | 10:07h | UTC

What we know — and don’t know — about Merck’s new Covid-19 pill – STAT

[Press release – not published yet] Merck announces oral antiviral Molnupiravir reduced the risk of hospitalization or death by approximately 50 Percent compared to placebo for patients with mild or moderate COVID-19.

Merck’s Covid-19 pill is great news but may not be a game-changer.

Video | A Pill For COVID? A Doctor Explains Molnupiravir.

Cohort study: Adding a new antihypertensive to existing regimens is associated with greater blood pressure reductions than maximizing dose.

6 Oct, 2021 | 09:57h | UTC

Adding a New Medication Versus Maximizing Dose to Intensify Hypertension Treatment in Older Adults: A Prospective Observational Study – Annals of Internal Medicine

News release: When blood pressure needs more control, what’s better: An additional drug or more of the same? – Michigan Medicine

Commentary: Adding an antihypertensive to existing regimens associated with greater BP reduction than maximizing dose, with some caveats in adherence – ACP Internist

Commentary on Twitter (thread – click for more)

Excited to see our paper in Annals today looking at blood pressure control regiments by adding multiple low dose meds vs. maxing dose then starting new meds. 🧵 https://t.co/3d4L2nZO4v

— Jeremy Sussman (@JeremySussman) October 5, 2021

RCT: An active strategy for diagnosing pulmonary embolism did not improve outcomes in patients hospitalized for COPD exacerbation.

6 Oct, 2021 | 09:52h | UTC

Effect of a Pulmonary Embolism Diagnostic Strategy on Clinical Outcomes in Patients Hospitalized for COPD Exacerbation: A Randomized Clinical Trial – JAMA (free for a limited period)

Commentary on Twitter

Among patients hospitalized for an exacerbation of #COPD, addition of an active diagnostic strategy for pulmonary embolism to usual care compared with usual care alone did not improve a composite set of health outcomes https://t.co/7mOi5lOBD8

— JAMA (@JAMA_current) October 5, 2021

SILENCE Randomized Trial: In patients at the end of life, prophylactic subcutaneous scopolamine butylbromide reduces the occurrence of the death rattle (noisy breathing caused by mucus in the upper respiratory tract).

6 Oct, 2021 | 09:54h | UTC

Effect of Prophylactic Subcutaneous Scopolamine Butylbromide on Death Rattle in Patients at the End of LifeThe SILENCE Randomized Clinical Trial – JAMA (free for a limited period)

Editorial: Preventing Death Rattle With Prophylactic Subcutaneous Scopolamine Butylbromide – JAMA (free for a limited period)

Author interview: Scopolamine Butylbromide for Preventing End-of-Life Death Rattle – JAMA

Commentary on Twitter

In a randomized clinical trial among patients near the end of life, prophylactic subcutaneous scopolamine butylbromide significantly reduced the occurrence of death rattle https://t.co/e6BDI5yirY pic.twitter.com/hHfhC2iYHh

— JAMA (@JAMA_current) October 5, 2021

Systematic review: Pretomanid for tuberculosis.

6 Oct, 2021 | 08:51h | UTC

Pretomanid for tuberculosis: a systematic review – Clinical Microbiology and Infection

Summary | WHO recommendations on the treatment of drug-resistant tuberculosis, 2020 update.

WHO announces updates on new molecular assays for the diagnosis of tuberculosis (TB) and drug resistance

WHO announces updated definitions of extensively drug-resistant tuberculosis

Supplement: Triumphs of Vaccination.

6 Oct, 2021 | 08:55h | UTC

Homepage: Triumphs of Vaccination – The Journal of Infectious Diseases

Triumphs of Immunization

Pertussis (Whooping Cough)

Hib Vaccines: Their Impact on Haemophilus influenzae Type b Disease

The Rotavirus Vaccine Story: From Discovery to the Eventual Control of Rotavirus Disease

Hepatitis B Vaccines

Triumph of Pneumococcal Conjugate Vaccines: Overcoming a Common Foe

Rubella Eradication: Not Yet Accomplished, but Entirely Feasible

Human Papillomavirus Vaccines

Smallpox

Live Attenuated Varicella Vaccine: Prevention of Varicella and of Zoster

Immunization Against Poliomyelitis and the Challenges to Worldwide Poliomyelitis Eradication

Influenza Vaccines: Successes and Continuing Challenges

Measles in the 21st Century: Progress Toward Achieving and Sustaining Elimination

Herpes Zoster Vaccines

Overview of the United States’ Immunization Program

The World of Immunization: Achievements, Challenges, and Strategic Vision for the Next Decade

Review: Eosinophilic Esophagitis.

6 Oct, 2021 | 09:51h | UTC

Eosinophilic Esophagitis: A Review – JAMA (free for a limited period)

Randomized trial: Budesonide orodispersible tablets maintain remission in patients with eosinophilic esophagitis

Clinical Guidelines for the Management of Eosinophilic Esophagitis

Eosinophilic Esophagitis: Review and Update

Is salt good for you after all? The evidence says no.

6 Oct, 2021 | 08:52h | UTC

Is salt good for you after all? The evidence says no – The Conversation

#ESCCongress – Cluster RCT: Among patients at increased risk for stroke, salt substitution (75% sodium chloride and 25% potassium chloride by mass) reduced the rates of stroke, major cardiovascular events, and death from any cause.

Systematic Review: Altered dietary salt intake for people with chronic kidney disease.

New WHO benchmarks help countries reduce salt intake and save lives.

RCT: Reduced-sodium added-potassium salt substitute reduces blood pressure in hypertensive patients

Potassium Enriched Salt Substitution Could Prevent a Large Number of Cardiovascular Deaths

Meta-Analysis: Effect of Reduction in Dietary Sodium on Blood Pressure Levels

Cluster Randomized Trial: Effect of Salt Substitution on Community-wide Blood Pressure and Hypertension Incidence

Review: Inhibition of platelet aggregation after coronary stenting in patients receiving oral anticoagulation.

6 Oct, 2021 | 08:46h | UTC

Inhibition of Platelet Aggregation After Coronary Stenting in Patients Receiving Oral Anticoagulation – Deutsches Ärzteblatt International

The diagnosis and management of endocrine side effects of immune checkpoint inhibitors.

6 Oct, 2021 | 08:44h | UTC

The Diagnosis and Management of Endocrine Side Effects of Immune Checkpoint Inhibitors – Deutsches Ärzteblatt International

Cohort study: Acute myocarditis following COVID-19 mRNA vaccination in adults aged 18 years or older is rare, and most cases are not severe.

5 Oct, 2021 | 10:07h | UTC

Acute Myocarditis Following COVID-19 mRNA Vaccination in Adults Aged 18 Years or Older – JAMA Internal Medicine

Editorial: COVID-19 Messenger RNA Vaccination and Myocarditis—A Rare and Mostly Mild Adverse Effect

Commentary on Twitter

New report on very rare acute myocarditis after mRNA vaccination in age 18+
5.8 cases/million after 2nd dose, 0.8/million 1st dose, all cases fully resolved with conservative managementhttps://t.co/Mfh5ImiSpW @KPSCALnews @KPSCalResearch @JAMAInternalMed

— Eric Topol (@EricTopol) October 4, 2021

Cohort study: Pfizer vaccine effectiveness against any infections declined from 88% during the first month after full vaccination to 47% after 5 months. Vaccine effectiveness against hospital admissions remained high; 87% within 1 month, and 88% at 5 months after full vaccination, with no significant waning.

5 Oct, 2021 | 10:09h | UTC

Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study – The Lancet

Commentary: Expert reaction to study on Pfizer-BioNTech vaccine effectiveness up to 6 months – Science Media Centre

Commentary on Twitter

Study of 3.4 million people @aboutKP @TheLancet

Vaccine efficacy against infections:
– First month post: 88%
– 5 months post: 47%

But vaccine efficacy against hospitalization (Figure):
– First month post: 87%
– 5 months post: 88 %https://t.co/1Gse0FKpoI pic.twitter.com/p9wyiaWGeg

— Vincent Rajkumar (@VincentRK) October 4, 2021